News and Press Releases
Owkin Announces First Patient Dosed in Phase I AI-optimized Clinical Trial of OKN4395, a First-in-Class EP2/EP4/DP1 Triple Inhibitor for Patients with Solid Tumors
OKN4395 is the first Owkin development program to leverage K1.0, Owkin’s AI-powered Operating System, from asset selection to clinical development optimization This asset is a highly selective triple inhibitor of...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 30, 2025
NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform
Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single blood sample ANGLE invited to present data at EACR-Illumina webinar on 6 February...
Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: January 29, 2025
Pfizer’s BRAFTOVI Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
Clinically meaningful and statistically significant results from the Phase 3 BREAKWATER trial show objective response rate of 61% with Pfizer’s BRAFTOVI combination regimen compared to 40% with investigator’s choice of...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 25, 2025
Clinical Trial Powered by Parsortix System Provides First-in-Class Data for Novel Approach to Cancer Treatment
Parsortix system used to identify patients with highly metastatic CTC clusters for targeted treatment New treatment strategy provides ‘uncharted opportunity’ to target metastasis responsible for the vast majority of cancer...
Category: Biotechnology, Clinical Trials, Drug Discovery, Pharmaceutical
Posted: January 24, 2025
HUTCHMED Announces NMPA Full Approval for ORPATHYS® (savolitinib) in China for Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
Indication expands to include treatment-naïve patients The 2021 conditional approval in previously treated patients converted to full approval. 14 January 2025 -- Hong Kong, Shanghai, and New Jersey, US --...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
BioMed X Institute Launches New Collaboration with Daiichi Sankyo in Cancer Therapy
German research institute BioMed X started a new partnership with Daiichi Sankyo, a Japanese pharmaceutical company, to advance the development of bi- and multi-specific biologics for treating solid tumors 14 January...
Category: Drug Discovery, Other, Pharmaceutical
Posted: January 14, 2025
Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma
Approval based on positive pivotal ICARIA-MM phase 3 study using the China-based IsaFiRsT real-world study as bridging data, which demonstrated Sarclisa and the standard treatment Pd, improved responses and long-term...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 13, 2025
New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma
Sarclisa SC formulation added to Pd for the treatment of R/R MM met the co-primary endpoints in the IRAKLIA phase 3 study, demonstrating non-inferiority compared to Sarclisa IV IRAKLIA is...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
PureTech Receives FDA Fast Track Designation for LYT-200 in Acute Myeloid Leukemia (AML)
Single agent and combination data from Phase 1b AML/MDS trial presented at ASH 2024 showed potential of LYT-200 to serve broad range of patients across various lines of treatment LYT-200...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: January 9, 2025
ENEA-Tech Biomedical Foundation Invests €6m in BetaGlue® Therapeutics
Brings 2024 Funding Round Total to €24m 16 December 2024 -- Milan, Italy -- BetaGlue Therapeutics S.p.A, an Italian clinical-stage oncology company developing an innovative radiotherapy platform for the targeted...
Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: December 16, 2024
BetaGlue Therapeutics SpA. Piazzetta Umberto Giordano 4, 20122 Milan, Italy
Ellipses Pharma Publishes Data from Ongoing Phase 1/2 Clinical Trial of EP0042
9 December 2024 -- London, UK -- Ellipses Pharma Limited, a global drug development company focused on accelerating the development of new oncology treatments, has published the latest data from...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: December 9, 2024
Longest Follow-Up Data Reported for Kite’s Tecartus CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
Only CAR T to Demonstrate Prolonged Overall Survival After Five Years Follow-Up in Relapsed/Refractory Mantle Cell Lymphoma ZUMA-2 Analysis Shows 91% Overall Response Rate, Including 73% Complete Response Rate, in...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: December 9, 2024
UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)
28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational...
Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 28, 2024
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG
Puma Biotechnology Announces Initiation of ALISCATM-Breast1 Phase II Trial of Alisertib in Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer
20 November 2024 -- California, US -- Puma Biotechnology, Inc, a biopharmaceutical company, announced the initiation of its ALISertib in CAncer (ALISCATM-Breast1) Phase II trial (PUMA-ALI-1201; NCT06369285) of alisertib in...
Category: Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: November 20, 2024
Johnson & Johnson submits applications in the U.S. and EU seeking approval of DARZALEX FASPRO®/DARZALEX® (daratumumab) as subcutaneous monotherapy for high-risk smouldering multiple myeloma
If approved, daratumumab will become the first treatment option for patients with smouldering multiple myeloma at high-risk of developing multiple myeloma, offering a novel approach to treat before the onset...
Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: November 8, 2024
Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG
